Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Previous Post
STAT+: Eli Lilly’s very bad day
Next Post
#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago